ALL NEWS

UPDATED RESULTS FROM PHASE I/IIA CLINICAL TRIAL FOR KOA

February 24, 2014

Preliminary analysis shows patient cartilage regrowth within 3 months

Cellular Biomedicine Group, Inc. announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tested  the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. On 11/01/ 2013 company  announced  completion of patient treatment for Phase I/IIa clinical trial for treatment of knee osteoarthritis with ReJoinTM,a human adipose-derived mesenchymal precursor cell. Patients had a clinically meaningful reduction in pain and increase in mobility, with a significant improvement from the baseline in some clinical scores without any serious adverse effects.  Three-month follow up data allow to announce reduced knee pain, improved knee mobility, and prolonged walking distance  as statistically significant.  MRI images demonstrate increased cartilage thickness in three months after therapy.

The trial is conducted by Shanghai’s Renji Hospital, a tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine.